Latest Commercialization News

Prospect Resources has confirmed significant gold by-product mineralisation at its Nyungu Central deposit, potentially boosting the economics of the Mumbezhi Copper Project in Zambia. Updated resource estimates incorporating these findings are expected in Q1 2026.

Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.

Viking Mines reports promising high-grade tungsten oxide assay results from its Linka Tungsten Project in Nevada, reinforcing the project's potential amid soaring global scheelite prices.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

DataWorks Group has reported a robust turnaround with a $1.1 million positive operating cash flow in Q2 FY26, underpinned by major government contracts and validated social impact from its BetStop™ platform.

AVITA Medical reported solid 11% revenue growth in 2025 and secured a $60 million credit facility to fuel its next phase of expansion, projecting up to 19% revenue growth in 2026.

Neometals and Mineral Resources’ joint venture Reed Advanced Materials has teamed up with electrochemical leader De Nora to pilot an integrated lithium hydroxide production plant, advancing sustainable battery materials technology.

Identitii Limited has locked in a $0.6 million R&D loan facility to bolster its growth amid rising BNDRY platform sales, supported by an expected $0.8 million R&D rebate and a $2.9 million Rights Issue.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

Gold Mountain Limited has reported strong assay results from diamond drilling at its Irajuba IR-1 prospect in Brazil, extending known rare earth mineralisation beyond previous targets with notably high magnet rare earth oxide content.

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.

DPM Metals has once again met its gold production guidance for 2025, marking eleven consecutive years of hitting targets, while preparing for a significant ramp-up at its Vareš operation.